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Abstract 
Background: Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive can-
didate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization 
of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs 
content and assess radiation-induced changes.
Methods: In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from 
PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treat-
ment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The com-
plete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched 
particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, 
miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, 
and qRT-PCR.
Results: In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) 
compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to 
untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we 
were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based 
flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-
7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite 
overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group 
(p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the 
intermediate group (p = 0.036).
Conclusions: Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplifi-
cation. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promis-
ing biomarker potential that requires further investigation in larger patient cohorts.
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Background
Prostate cancer (PCa) is one of the most common malig-
nancies in men [1]. Despite controversies in the use of 
prostate specific antigen (PSA) for PCa screening, it is 
one of the most widely utilized biomarkers, and its clini-
cal use has an undeniable clinical importance [2]. None-
theless, PSA alone has not provided accurate diagnostic 
and prognostic information. Recently, “liquid biopsies” 
such as circulating exosomes have gained increasing 
importance [3]. These vesicles not only function in 
removing cellular artefacts, but also play an important 
role in cell-to-cell communications which is due to 
nucleic acid, protein cargo that is deemed to reflect cell 
biology of originating tumor cells [4, 5]. Thus, the spec-
trum of exosome research is split into isolation from 
biofluids, functional analysis, and its  potential use in 
clinical assays. Studies have shown that extracellular vesi-
cles including exosomes are a better source of selective 
miRNAs than the whole blood [6]. The growing interest 
in miRNAs, a cargo component of exosomes, is due to 
its stability as they are either bound to specific proteins 
e.g. Argonaute2 protein complex (Ago2) or are con-
tained in exosomes protecting them from lysis by RNase 
in blood. miRNAs (circulating and bound) have been 
widely investigated in PCa and have  promising applica-
bility as prognostic and/or predictive markers [7]. Cellu-
lar stress conditions with microenvironment adaptations 
involve the release of miRNAs, miRNAs processing as 
well as changes in miRNAs function [8]. In cancer, miR-
NAs act both as oncomirs and tumor suppressors which 
may equally play a role in treatment response to differ-
ent stressors including radiation treatment [9, 10]. Exoso-
mal RNAs mediate genomic instability of recipient cells 
indicating a  stress-induced RNA cargo released due to 
radiation [11]. Certain miRNAs (e.g. miR-145) have been 
found to promote cancer proliferation and radioresist-
ance [12, 13] which underlines the clinical potential of 
miRNAs in radiation oncology [14].
The technical challenges in implementing a robust 
method for detection of site-specific exosomes in func-
tional studies are well-known [15]. Many techniques for 
exosome isolation and recovery of exosomal miRNAs 
have been published showing that the functional out-
comes of exosomes are technique- and sample-depend-
ent (e.g. biofluids, cell culture samples) [16]. In clinical 
settings, limited volume of blood may also restrict  exo-
some concentration and miRNA profiling. Moreover, dif-
ferences in sample storage, processing, RNA extraction 
and amplification (e.g. qRT-PCR, deep sequencing) have 
substantial impact on data generation and clinical appli-
cability. miRNAs associated with PCa and radiotherapy 
response are summarized in our recent paper, although 
literature is very limited on the topic [5]. Exosomes 
therefore represent a promising biological marker  for 
potential optimization of PCa radiotherapy.
Methods
Ethics statement and patient serum sampling
The ethical approval for this study was obtained from 
the Kantonale Ethikkommission Bern, Switzerland. We 
planned a comparative analysis of 5 candidate miRNAs at 
baseline [before radiation therapy (RT)] and after RT by 
setting up a cohort of 11 patients and 3 controls as a pilot 
phase  from a prospective  study—SAKK63/12 (http://
sakk.ch/en/sakk-provi des/our-trial s/uroge nital -tumor 
s/sakk-6312/). Diagnosis of PCa was initially confirmed 
by prostate biopsy and definition of a Gleason score 
(Table  1). All patients were classified into intermedi-
ate risk (IR) or high-risk groups (HR) based on National 
Comprehensive Cancer Network (NCCN) classification 
[17]. The post-radiation follow-up sampling was per-
formed at 3 months’ time interval (± 2 months) as paired 
samples according to SAKK 63/12 study protocols (IR_F, 
HR_F). Additionally, a third group included three vol-
unteers who visited clinic for reasons unrelated to PCa 
(n = 3).
Exosome isolation from serum
Blood was collected in S-monovette® 9  ml Z-Gel blood 
collection tube (Sarstedt AG., Germany), kept at room 
temperature for half an hour followed by centrifugation 
at 1500g for 10  min to separate serum. Afterwards, the 
serum samples were filtered through RNA/DNA free 
0.22  µm sized syringe filter and processed for exosome 
isolation. Commercially available polyethylene glycol 
(PEG) products were used for enrichment of exosomes. 
Total Exosome Isolation Kit (Cat. No. 4478360) from 
Invitrogen was used according to manufacturers’ instruc-
tions for exosome isolation from serum samples. Briefly, 
1 ml of serum was added with 250 µl of isolation reagent 
and mixed well by gentle vortexing. The solution was 
incubated at 4 °C for 1 h and then centrifuged at 10,000g 
for 10 min at room temperature. The pellet was washed 
twice with 1  ml of PBS and discarded. The final pellet 
containing exosomes was re-suspended in 100  µl resus-
pension buffer and then stored at − 20  °C prior to RNA 
isolation [18].
Nanoparticle tracking analysis
For nanoparticle tracking analysis (NTA), exosome sus-
pension was diluted in PBS to reach the concentration 
range of 2 × 108 − 8 × 108 particles/ml as required by 
NanoSight NS300 (NanoSight NTA 2.3 nanoparticle 
tracking and analysis) [19]. Samples were introduced 
into the Flow-cell top plate chamber (temperature: 25 °C) 
and the camera level was set to obtain an image that had 
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sufficient contrast to clearly identify particles while mini-
mizing background noise with video recording (cam-
era level: 10). With violet embedded laser (405 nm, max 
power < 70 mW) using continuous flow of sample, 360 s 
videos were captured for each sample.
Transmission electron microscopy
Five microliter of exosomes suspension was added onto 
200 mesh  Formvar® coated and glow discharged copper 
grids for 20 min. Excess suspension was removed with fil-
ter paper and then fixed by placing the grids on a drop 
of 2% paraformaldehyde for 20  min. Grids were then 
washed with PBS droplets for 6 times and fixed with 1% 
glutaraldehyde before washing them with water drop-
lets for 6 times. The exosomes were negatively stained 
by placing the grids on a droplet of 4% uranyl acetate for 
10 min and air dried. Samples were then examined with 
a transmission electron microscope (CM12, Philips, Ein-
dhoven) equipped with a digital camera (Morada, Soft 
Imaging System, Münster, Germany) and image analysis 
software (iTEM) [20].
Western blot analysis
We performed western blotting using primary antibod-
ies for exosomal surface markers CD81 (SC-7637, Santa 
Cruz), and CD63 (1:300 dilution; SC-365604, Santa 
Cruz), secondary anti-mouse (1:2000 dilution; SC-2005) 
HRP conjugated antibodies (Fig.  3c). Briefly, 100  µl of 
extracted exosome suspension was mixed with RIPA 
buffer for 15 min on ice. The suspension was then mixed 
with Laemmli buffer containing 5% Beta-mercaptoetha-
nol and denatured at 90 °C for 5 min. The protein sepa-
ration was done at constant voltage of 150 V for 60 min. 
After blocking with 5% Bovine Serum Albumin for 1 h at 
room temperature, the immune-blot Polyvinylidene dif-
luoride membrane was incubated overnight with primary 
antibodies at 4  °C followed by incubation with second-
ary antibody at 1:2000 dilution for 1 h at room tempera-
ture. Finally, SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) was used, then exposed to 
X-ray film for image detection.
Flow cytometry
We performed flow cytometry targeting the surface 
markers CD63, CD9 by bead capture methods using 
commercial kit [21]. Exosomes mixed in isolation buffer 
was incubated with CD63 coated  Dynabeads® mag-
netic beads (Cat. No. 10606D, Life technologies, USA) at 
2–8  °C overnight. On second day, the exosomes bound 
to magnetic beads were stained with FITC-CD9 (Cat. 
No. MA1-19557) monoclonal antibody (MEM-61), and 
PE-CD63 (Cat. No. MA1-19650) monoclonal antibody 
(MEM-259) following protocol. Ten thousands events 
were collected using flow cytometry (BD LSR Fortessa, 
BD FACS Diva software). The subsequent analysis was 
performed on FlowJo (FlowJo Engine v3.05470).
RNA extraction and quantification
The Total Exosome RNA and Protein Isolation kit (Cat. 
No. 4478545, Invitrogen) designed for isolation of small 
RNA from enriched exosome preparation was used fol-
lowing manufacturer’s recommendations. RNA concen-
tration and quality were evaluated by Bioanalyzer 2100 
Expert (Agilent Technologies, Inc.) in conjugation with 
Small RNA analysis kit (Cat. No. 5067-1548) using Agi-
lent 2100 Expert software.
Table 1 Patient clinicopathological characteristics
IR intermediate risk group, HR high risk group, NCCN National Comprehensive Cancer Network
Sample ID Age Pre-treatment PSA 
(ng/ml)
Pathological stages Gleason score Risk group 
based on NCCN 
guidelines
B15 67 5.4 cT2a cN0 cM0 3 + 4 IR
B16 76 15.8 cT2a cN0 cM0 4 + 3 IR
B17 78 6.3 cT2b cN0 cM0 3 + 4 IR
B03 82 24.4 cT1c cN0 cM0 8 HR
B60 68 17.6 cT2a cN0 M0 3 + 4 IR
C73 66 0.9 pT2a pN0 M0 3 + 4 IR
B09 71 13.30 cT3a cN0 M0 4 + 5 HR
C05 74 0.40 pT3 pN0 M0 3 + 4 HR
C12 67 0.20 pT3a pN0 M0 3 + 4 HR
B71 54 7.2 cT1c cN0 cM0 3 + 3 IR
C59 73 0.8 pT3a pN0 cM0 4 + 4 HR
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TaqMan MiRNA assays
The qRT-PCR quantification was performed on total of 
25 samples to determine miRNA recovery from serum 
exosomes. Five miRNAs were shortlisted from previ-
ously published literature that are relevant to PCa and 
RT (Additional file  1: Table  S1) [5]. Samples were pro-
filed using specific individual TaqMan MiRNA Assay 
(RNU48; Assay-ID: 001006, let-7a-5p; Assay-ID: 000377, 
hsa-miR-145; Assay-ID: 002278, hsa-miR-141-3p; Assay-
ID: 000463, hsa-miR-21; Assay-ID: 000397, hsa-miR-
99b; Assay-ID: 000436). To perform standard qRT-PCR 
quantification, 2 µl of RNA elution was used for reverse 
transcription step, while 0.66 µl of cDNA was then used 
for amplification cycle. Each reactions was performed in 
triplicates in 10  µl of reaction volume [22]. Initial data 
analysis was performed using the SDS v1.4 software 
(Applied Biosystem) supplied with the real-time 7500 
Fast RealTime PCR System.
The relative expression level of miRNAs was calcu-
lated based on average threshold cycle (CT) value from 
three replicates. The relative quantification—also called 
fold change—in miRNA expression between radiated 
(ΔCTpost) versus baseline patient samples (ΔCTpre) was 
determined by using the  2−ΔΔCT comparative method.
Statistical analysis
Data show the mean of independent biological experi-
ments with the standard error (± SE). The two-sided 
paired, unpaired or the one-sample t-test were used for 
statistical analysis and a p-value < 0.05 was deemed statis-
tically significant. The software used for statistical analy-
sis was R package (http://www.R-proje ct.org).
Results
Exosome concentration varies after radiation exposure
We investigated exosome isolation workflow in  1  ml 
of serum using PEG based commercial kits followed by 
its characterization using TEM, Nanosight, and FACS 
[23]. We first proceeded with filtration of serum using 
0.22  µm sized filter so we expected filtrate containing 
particles below that size [24]. To enrich the isolation of 
exosomes, PEG was added and the resulting pellets were 
suspended in buffer for further characterization steps. 
Using Nanosight, we observed approximately 1.89 × 1010 
particles from 1 ml of serum from healthy controls. The 
overall mean concentration of vesicles were higher in 
PCa patients (5.02 × 1010 particles/ml), which increased 
further in post radiation serum samples (6.37 × 1010 
particles/ml; p = 0.52) (Fig.  1). Majority of vesicle size 
obtained was between 50 and 200  nm which is consid-
ered as ideal size for exosomes (Fig.  2). The size dis-
tribution of exosomes when compared to PCa versus 
control, before and after radiation showed no significant 
difference (data not shown) which is similar to previ-
ous findings [25]. We performed western blot targeting 
CD63, CD81 tetraspanins surface markers known to 
be enriched in exosomes. The result confirmed posi-
tive bands for both proteins however the density varied 
across samples which demonstrates different expression 
of surface proteins (Fig. 3c). The western blot hybridiza-
tion result were complementary to FACS result in deter-
mining the presence of exosomal surface marker protein 
in the sample. In TEM analysis, vesicles resembling the 
size of exosomes were observed as shown in Fig.  3a, b. 
The cup-shaped structure confirmed the morphological 
similarity to exosomes [18].  
For flow cytometry analysis, CD63-beads bound 
exosomes were first visualized on forward (FSC) ver-
sus side scatter (SSC) graph to gate on bead singlets. 
Exosomes isolated using PE-CD63 antibody was flow-
sorted using PE-positive gating while for those isolated 
with FITC-CD9 were flow-sorted using FITC-positive 
gating separately (Fig. 4a, b). It was distinct from data the 
mean fluorescent intensity for CD63 antibody was higher 
than for CD9 suggesting higher expression of CD63 sur-
face marker in exosomes derived after radiation. Use of 
magnetic beads labelled with exosomal surface specific 
antibodies may increase specificity in isolating pure 
exosomes, however proportion of those beads may not 
correlate the real count of exosomes. Thus, we confined 
our result and discussion only as a tool to identify serum 
exosomes using FACS.
Low concentration of exosomal miRNAs were characterized 
by qRT-PCR
Total Exosome RNA and Protein Isolation kit was used 
to extract RNA from exosome suspension following 
Fig. 1 Change in longitudinal expression of exosomes in serum 
samples. The boxplot shows the increasing trend of exosome 
concentration after radiation therapy. The time difference between 
baseline (no radiotherapy) and FUP (radiotherapy) sampling was at 
least 28 days
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Fig. 2 Nanosight analysis. The x-axis indicates the size distribution of particles, while y-axis shows the relative counts. The red-smear denotes 
variation as standard error of mean. a Size of most of the particles was 92 nm in baseline (no radiation) sample, b size of  most of the particles were 
107 nm in FUP (radiation)
Fig. 3 Characterization of serum derived exosomes. a, b Transmission electron microscope images of exosomes. Presence of cup-shaped vesicles 
sized below 200nm; c western blot demonstrating the expression of CD63, and CD81 in selected patients
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manufacturers instruction, which uses glass-fiber fil-
ters with affinity to RNA [26]. The miRNAs recovered 
from exosomes that were initially derived from 1  ml of 
serum was below 1000 pg/µl indicating low yield in both 
baseline and post-radiation samples, and controls. As 
an example, Agilent 2100 Bioanalyzer Small RNA Chip 
result showed RNA at concentration of 9.2  pg/µl while 
miRNA constituted approximately 51% of total RNA 
(Fig. 5). The qRT-PCR result based on average Ct values 
for all five miRNAs indicate successful recovery of miR-
NAs except for RNU48, from all the 25 samples. The data 
showed hsa-miR-21-5p (average Ct value = 27.82), and 
hsa-miR-7a-5p (average Ct value = 28.98) were in high 
copy numbers while hsa-miR-99b, hsa-miR-141-3p, hsa-
miR-145 were less with average Ct values of 32.50, 34.72, 
32.46 respectively.
The comparison of all five miRNAs in risk groups 
categorized as before (IR, HR) and after radiotherapy 
(IR_F, HR_F) using Ct values gave mixed results; hsa-
miR-141-3p, hsa-miR-145-5p, hsa-miR-99b-5p were not 
significantly different across risk groups. The evaluation 
of hsa-let-7a-5p, and hsa-miR-21-5p showed distinct 
expression in both risk groups (Fig.  6a). Especially, in 
high-risk group, both miRNA expression became more 
abundant post radiation which might indicate it has pro-
tective effect; the argument being the expression became 
comparable to control group without known prostate 
disorders. The expression of hsa-let-7a-5p, which could 
discriminate radiation response in HR group, was abun-
dant in exosomes after radiation (p = 0.037). The expres-
sion of hsa-miR-21-5p, which could not discriminate HR 
from IR patients at baseline, was abundant in exosomes 
after radiation in HR groups only (p = 0.036). The miRNA 
expression referred to a reference group, baseline ver-
sus post-radiated samples showed heterogeneous dis-
tribution as expected (Fig. 6b). The upregulation of two 
miRNAs namely hsa-let-7a-5p (fold change 2.24) and 
hsa-miR-21-5p (fold change 1.77) potentially indicating 
an induction due to radiation.
Discussion
Recent studies reported the variability in exosome sub-
types and cargo composition emphasizing the impor-
tance of isolation and characterization methods. In 
clinical settings, the success of an optimal liquid biopsy 
workflow is dependent of small sample volumes that 
allow proper characterization of the exosomal cargo. 
A better characterization of exosomes origin through 
molecular and genetic analysis and changes induced by 
treatment could provide valuable knowledge for treat-
ment personalization. Radiotherapy is a primary curative 
modality in PCa [27]. Although previous studies focused 
on isolation, and characterization of exosomes, varia-
tion in paired patient samples before and after radiation 
has never been investigated. To our knowledge, this is 
the first study to assess an exosome isolation workflow 
for PCa radiotherapy. We demonstrated that despite min-
imal volumes and extraction of exosomal miRNAs, qRT-
PCR-based expression analysis is technically feasible.
Although a minimal volume threshold of serum 
required for optimum yield of exosomes is an important 
limiting factor, we have isolated exosomes from a vol-
ume of 1 ml. A titration study found that the volume of 
input serum positively correlates to the exosome yield 
[28]. In this study, median follow-up sampling time inter-
val was 93 days (min 34; max 148) after radiation which 
is an important factor to be considered. From biologi-
cal perspective, quantitative and qualitative variation of 
exosomes and its RNA molecules would be meaningful 
in defining their predictive markers for specific thera-
pies, establishing a basis for detection of a temporal 
relationship [29, 30]. In general, higher concentration 
of exosomes in patient samples could indicate radiation 
specific induction; however, more specific  molecules 
such as DNA damage markers deserve further investiga-
tion [14]. Moreover, exosome vesiculation is proposed 
to be influenced by multiple factors which may interfere 
with exosome release and its content [16]. The method 
used to isolate exosomes influences the quality and 
quantity of exosomes [28]. The PEG has long been used 
for precipitation of small particles such as viruses that 
may precipitate exosomes present in the samples (e.g. 
blood, cell culture supernatant) [31]. Despite low purity, 
enrichment of vesicles can be achieved by filtration and 
certain optimization methods that enriches vesicles sig-
nificant in quality and quantity for biomarker research 
[18]. The input of less serum volumes may cause breaking 
of vesicles in other methods such as ultracentrifugation 
causing low particle recovery and biased downstream 
analysis [32]. The PEG reagent forms polymer for better 
precipitation of exosomes yet preserves their biological 
activities to be used in basic and clinical research [33]. In 
Fig. 4 Analysis of exosomes by flow cytometry using CD63 coated magnetic beads. Exosomes were first visualized on forward (FSC) versus 
sidescatter (SSC) plots to gate on the respective exosomes bound to beads population, after gating on singlets. a Typical SSC versus PE-CD63 
plots for exosomes isolated from the serum of two donor samples. As comparison, a typical plot for serum derived exosomes from prostate cancer 
patients using CD63 antibodies at baseline and post-radiation. b Typical SSC versus FITC-A plots for exosomes using CD9 antibodies at baseline and 
post-radiation. The graph shows increased CD63 representing exosomes compared to CD9 representing surface markers after radiotherapy
(See figure on next page.)
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particular, PEG-based exosome isolation provides con-
sistent measurements which are in general consensus to 
most extravesicular research findings [34].
The Nanosight measurements showed consistent data 
for exosomes that has been corroborated in other studies 
with conventional ultracentrifugation methods. This sug-
gests that PEG method is a suitable tool in vesicles recov-
ery from serum [35]. The Nanosight technology relies on 
laser light scattering microscopy on Brownian motion of 
the particles providing size-based particle count as well 
as respective concentration. This might have limitations 
in precisely capturing exosomes alone excluding noise 
created by lipoproteins, protein aggregates,  and other 
biological vesicles from serum [19]. Another criticism of 
using NTA technology is the evidence of  operator han-
dling bias that may influence the accuracy and reproduc-
ibility of the measurements [36]. As the isolation and 
enrichment of exosomes from biofluids is an elaborate 
task, technical variations may  impact interpretation of 
results, especially in comparing individual cases. Thus, 
sample  grouping would arguably make more sense in 
the interpretation of radiation-induced changes. We have 
stratified our samples before and after irradiation. Patient 
variability may show endogenous variability in terms of 
size and distribution of exosomes, an ideal protocol in 
NTA that is applicable for each and every sample would 
be difficult to validate, despite certain possibilities to 
reduce those variation by optimizing NTA software set-
tings [19, 37].
Our FACS experimental results are limited in outlining 
one possible approach in exosome characterization work-
flow, though implication of exosomal surface markers is 
briefly discussed. The FACS result may lead to a hypoth-
esis that CD9 surface marker is less expressed compared 
to CD63 in serum exosomes from PCa patients. This may 
also indicate the exosomal sub-population theory regard-
ing their concentration, heterogeneous surface markers, 
and contents are influenced by multiple factors (e.g. clini-
cal phenotypes) [38]. In contrast, studies have also found 
exosomes representing higher amount of CD9 surface 
marker in advanced and chemo-resistant PCa compared 
to others [39]. Such variation showing selective enrich-
ment of exosomes can also be due to methodological 
variation used for their isolation and processing [15, 
40]. While NTA technologies are limited to size based 
discrimination, use of beads (4.5  µm diameter) labelled 
with surface markers for exosomes make it possible to 
characterize them by FACS [41]. In our pilot study, we 
used  Dynabeads® coated with primary monoclonal anti-
body specific for human exosomes surface antigen CD63 
without knowing the concentration of optimal antibod-
ies required for samples. A standard titration curve 
using standard exosome concentration will be essential 
to ensure most correct number of exosomes captured by 
beads. Heterogeneous exosome populations with varying 
Fig. 5 Small RNA profile from serum exosomes measured by Agilent Small RNA kit. The representative electropherograms showing nucleotide size 
(x-axis) between 4 and 40 as indicated my vertical lines is the region for miRNAs while peak at 4 nucleotide represents internal standards. The y-axis 
represents fluorescence units (FU)
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levels of surface antigen (e.g. CD63, CD9) or their relative 
expression is important to consider which may allow to 
correctly interpret biological causes of (sub) population 
and concentration of exosomes in biofluids [42, 43]. It 
is important to note that multiple numbers of exosomes 
may bind on a bead which may potentially bias the exact 
number of exosomes in the given volume of specimen. 
The detection limit of flow cytometers is 200 nm which 
is the size threshold used to differentiate exosomes from 
other microvesicles [44]. Despite certain limitations by 
FACS, use of magnetic beads solve one important aspect 
of identifying exosome in biofluids [43]. Moreover, recent 
technical upgrades in FACS targeting multiple surface 
markers may provide desired level of standardization 
methods that can be widely used for routine exosomes 
characterization workflow in future [44, 45].
In subsequent RNA extraction step, other RNA spe-
cies such as full length 18S and 28S rRNA peaks were 
not observed in electropherograms which is in congru-
ence to other similar study [28]. The choice of exosome 
Fig. 6 a Relative expression of hsa-let-7a-5p and hsa-miR-21-5p in risk groups. The relative expression of hsa-let-7a-5p, and hsa-miR-21-5p in 
risk groups were evaluated by measuring the difference in threshold cycle number. The expression of hsa-let-7a-5p was significantly different 
between HR, and HR_F (p = 0.037) while, hsa-miR-21-5p expression was significantly different between HR, and IR following radiation (p = 0.036). 
This may mean the function and role of hsa-miR-21-5p in PCa differs in response to radiation, based on risk category. IR intermediate risk without 
radiotherapy, HR high risk group without radiotherapy, IR_F intermediate risk post radiotherapy, HR_F high risk post radiotherapy. One asterisk 
indicates significant (p-value < 0.05) difference in miRNAs expression level between compared groups. b Fold change results for miRNAs. The fold 
change values of five miRNAs are shown. The y-axis represents log transformed  2−ΔΔCt value calculated in radiation treated patients relative to 
pre-radiotherapy (baseline)
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isolation method was found to selectively enrich miRNA 
expression during qRT-PCR e.g. miR-16, let-7a [46]. Due 
to low sample input volume, the yield of RNA was less 
and was difficult to measure by Qubit, Nanodrop [47]. 
The possible explanations could be due to multiple wash-
ing steps in protocol of Total Exosome RNA and Protein 
Isolation kit that washed away certain amounts of small 
RNA. The rate of miRNA synthesis at site of cancer and 
its half-life in biofluids determine their expression level. 
The turnover of miRNA in circulating exosome is not yet 
clear although the median half-life of other mRNA mol-
ecule is thought to be around 2  min [48]. Due to mul-
tiple reasons, it is challenging to confirm if the initial 
RNA volumes were comparable between samples, which 
would affect the downstream process till expression anal-
ysis [49]. A recent publication using mass spectrometry 
analysis showed small RNAs as major content of serum 
exosomes derived from colon cancer patients [50]. Novel 
approaches for scaling up exosome concentration may 
further enhance the possibility of recovering higher 
miRNA concentration in the serum.
In qRT-PCR analysis, there is no consensus in 
the  choice of reference gene derived from exosomal 
RNA cargo for data normalization [51–53]. We tested 
RNU48 that has been used in other studies to normalize 
miRNAs in qRT-PCR analysis but gave “undetermined” 
result [54, 55]. RNU48 has been found to be dysregulated 
in certain cancer types such as breast and head and neck 
cancers that could introduce bias in the miRNA expres-
sion analysis [56]. Conclusively, the RNU48 was not pre-
sent in detectable amount by qRT-PCR so we propose 
it should not be used as a reliable control for exosome 
study. We resorted in calculating average expression data 
for each set of samples for each miRNA target; a com-
mon approach used to normalization by taking mean Ct 
values from a set of miRNAs as similar to global mean 
normalization [57, 58].
The expression of hsa-let-7a-5p increased significantly 
post radiation in HR_F (p = 0.037). The hsa-miR-21-5p 
expression remained the same in the IR group while dif-
fered significantly in the HR_F (p = 0.036). The distinct 
expression of miRNAs in IR versus HR groups may have 
clinical ramifications (Fig.  6a). Four miRNAs (miRNA-
21, miRNA-34a, miRNA-125, and miRNA-126) observed 
in comparison of  PCa to benign prostatic hyperplasia 
demonstrate the heterogenity in miRNA expression 
[59]. With regard to the heterogeneity of expression 
data, another study found different sets of miRNAs (let-
7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p 
and miR-25-3p) that discriminated benign prostatic 
hyperplasia patients from PCa [60]. While miR-21-5p 
better distinguished PCa from benign prostatic hyper-
plasia, exosomal  let-7a-5p was found to be differentially 
expressed in patients with Gleason score ≥ 8 versus ≤ 6 
[6]. The expression of hsa-let-7a family miRNAs is regu-
lated in prostate cancer [61], and are altered by ionizing 
radiation [62]. Exosomal biogenesis still requires impor-
tant elucidation, therefore its reliability as a disease bio-
marker depends on the  study design, and also on the   
specific clinical question [6, 63, 64]. Unless there is a 
stringent method to define association of exosome yield 
and its content with specific clinical endpoints, the cross-
referencing from previous studies will still raise questions 
on its biomarker application [65]. With pilot samples, we 
demonstrated the feasibility to detect radiation-associ-
ated miRNAs in serum exosomes. Given limited sample 
size and important clinical heterogeneity,  further stud-
ies in larger datasets are warranted.
Conclusions
Our preliminary findings can be summarized as follows: 
(I) for exosome isolation, PEG-based assay is an efficient 
and reliable method, especially in clinical studies with 
limited sample volumes; (II) for exosome characteriza-
tion, TEM, Nanosight and FACS can be used with reliable 
and reproducible results; (III) for miRNAs identification, 
the amplification was feasible using qRT-PCR; and (IV) 
differential expression of serum exosomal miRNAs are 
induced by PCa radiotherapy, which may have potential 
value as prognostic and predictive biomarkers.
Limitations of the study
This publication is based on initial feasibility part of a 
larger clinical prospective study which has some limita-
tions. Clinical and pre-clinical research on exosomes and 
its relation with cancer, specifically localized prostate can-
cer is still at early stage. Biomarker studies in localized 
PCa are challenging and require proper technical valida-
tion before implemention in larger sample cohort. To our 
knowledge, there has been little or no previous research 
done in localized disease comparing effects of radiother-
apy in paired samples. The idea behind publishing early 
findings from small sample set was to confirm the feasibil-
ity of available techniques in exosome research. Likewise, 
miRNAs and its specificity to a definite disease state and 
treatment response might vary across individuals due to 
disease heterogeneity. Notably, in studies with smaller 
sample size, molecular and clinical heterogeneity of PCa 
may significantly affect miRNA expression [66]. Although 
ionizing radiation may induce release of exosomes at site 
of radiation, clinical presentation, size of tumor may influ-
ence expression and eventual release to biofluids distant 
from the site of radiation. There is paucity in data regard-
ing comparative analysis on yield of exosomes at site of 
disease and distant biofluids. It is evident that PEG helps 
to isolate exosomes by forming a polymer complex, there 
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is mixed interpretation on how residual PEG interacts 
with exosomes, and other particles present in serum. 
Similarly, methodological comparison of exosome isola-
tion protocols has shown to include non-exosome asso-
ciated miRNAs [67]. Our panel of miRNAs for targeted 
amplification is a unique set as it was selected from pre-
viously  published PCa literature. Despite limitations, 
the  proposed protocol is robust  and reproducible which 
may be used as  a standard workflow for exosome-based 
biomarker research (Additional file 2: Figure S1).
Additional files
Additional file 1: Table S1. The functions and characteristics of miRNAs.
Additional file 2: Figure S1. Workflow of miRNA Profiling. The overall 
serum exosome isolation and its content characterization workflow 
consists primarily of two steps. (1) Isolation and enrichment of exosomes 
from serum. (2) miRNA extraction of exosomes and characterization by 
qRT-PCR.
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